Day One Expands Pipeline With Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting Ptk7 in Solid Tumors for Adult and Pediatric Cancers
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.